Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis

J Lu, J Lu, W Chen, Y Huo, X Huang, J Hou, Chinese Medical Doctor Association Hematology Branch, J Lu, J Lu, W Chen, Y Huo, X Huang, J Hou, Chinese Medical Doctor Association Hematology Branch

Abstract

The aim of this study was to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). This retrospective study enrolled 940 newly diagnosed inpatients (median age, 59 years; immunoglobulin (Ig)D isotype, 6.5%) with complete follow-up data at three centers. In all, 85.8% of patients were of Durie-Salmon stage III and 48.3% were of International Staging System (ISS) stage III at diagnosis. Also, 9.6% of patients had extramedullary plasmacytoma. Compared with IgG, IgD-type patients were diagnosed at a younger age, and more patients were of ISS stage III, with hypercalcemia, elevated levels of lactate dehydrogenase, hyperuricemia, renal dysfunction and 1q21 amplification (P=0.03). The overall survival (OS) benefit was more prominent in IgG than in IgD when patients received bortezomib; however, they showed no significant difference when they received older therapies such as melphalan combined with prednisone or vincristine combined with adriamycin and dexamethasone. Fluorescence in situ hybridization (FISH) results showed that 17.6% had 17p13 deletion. Conventional cytogenetics revealed that 13.3% were hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) did not show any survival benefit compared with those with a normal karyotype (77.4%). Median OS and progression-free survival for all patients were 54 and 26 months, respectively. Significant factors for survival by multivariate analysis were gender, ISS stage, number of FISH abnormalities and extramedullary disease. MM in mainland China presents with different features, with patients being of younger age and having higher risk and more survival benefit in IgG patients receiving bortezomib.

Figures

Figure 1
Figure 1
OS and PFS in IgG and IgD patients who received bortezomib.
Figure 2
Figure 2
OS and PFS in IgG and IgD patients who received MP and VAD.
Figure 3
Figure 3
OS and PFS in IgG patients who received bortezomib and MP/VAD.
Figure 4
Figure 4
PFS for patients with hyperdiploid, hypodiploid and normal karyotypes.
Figure 5
Figure 5
OS for patients with hyperdiploid, hypodiploid and normal karyotypes.

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–236.
    1. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158:91–98.
    1. Jain RV, Mills PK, Parikh-Patel A. Cancer incidence in the south Asian population of California, 1988-2000. J Carcinog. 2005;4:21.
    1. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501–5506.
    1. Wang Q, Wang Y, Ji Z, Chen X, Pan Y, Gao G, et al. Risk factors for multiple myeloma: a hospital-based case-control study in Northwest China. Cancer Epidemiol. 2012;36:439–444.
    1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
    1. Geng C, Liu N, Yang G, Liu A, Leng Y, Wang H, et al. Retrospective analysis of 264 multiple myeloma patients. Oncol Lett. 2013;5:707–713.
    1. He J, Yang L, Meng X, Wei G, Wu W, Han X, et al. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma. Am J Med Sci. 2013;345:88–93.
    1. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
    1. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–3495.
    1. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358–360.
    1. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25:906–908.
    1. Chen HF, Wu TQ, Li ZY, Shen HS, Tang JQ, Fu WJ, et al. Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Oncol Targets Ther. 2012;5:329–334.
    1. Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411–416.
    1. Hayashi T, Yamaguchi I, Saitoh H, Takagi M, Nonaka Y, Nomura T. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis. Intern Med. 2003;42:605–608.
    1. Schmielau J, Teschendorf C, Konig M, Schmiegel W, Graeven U. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leuk Lymphoma. 2005;46:567–569.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa